EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer

Zedao Liu, Zhenlin Yang, Junqi Wu, Wenjie Zhang, Yuxuan Sun, Chao Zhang, Guangyu Bai, Li Yang, Hongtao Fan, Yawen Chen, Lei Zhang, Benyuan Jiang und 40 weitere

Cell · 2025-05 · 188 (11) · 3081-3096.e19

DOI: 10.1016/j.cell.2025.03.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2025-05. Verfasst von Zedao Liu und 51 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Peking University, Beijing 100871, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Single-Cell Analysis, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Peking University, Shanghai Municipal Health Commission, China Academy of Space Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeutic outcomes remain underexplored. We applied single-cell RNA and TCR sequencing (scRNA/TCR-seq) to analyze surgical tumor samples from 234 NSCLC patients post-neoadjuvant chemo-immunotherapy. Analyses revealed five distinct TIME subtypes with varying major pathological response (MPR) rates. MPR patients had elevated levels of FGFBP2+ NK/NK-like T cells, memory B cells, or effector T cells, while non-MPR patients showed higher CCR8+ Tregs. T cell clonal expansion analyses unveiled heterogeneity in non-MPR patients, marked by varying expansions of Tex-relevant cells and CCR8+ Tregs. Precursor exhausted T cells (Texp cells) correlated with recurrence-free survival, identifying a patient subgroup with reduced recurrence risk despite lack of MPR. Our study dissects TIME heterogeneity in response to chemoimmunotherapy, offering insights for NSCLC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSingle-Cell AnalysisProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansTumor MicroenvironmentFemaleMaleMiddle AgedAgedImmunotherapyKiller Cells, NaturalT-Lymphocytes, Regulatory

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Biomedical Pioneering Innovation Center (BIOPIC) and School of Life Sciences, Peking University, Beijing 100871, China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Key Labor…
  • Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Förderung

  • Peking University
  • Shanghai Municipal Health Commission
  • China Academy of Space Technology
  • Beijing Nova Program
  • Center for Life Sciences
  • Changping Laboratory
  • Chinese Academy of Sciences
  • Guangdong Provincial People's Hospital

Zitieren

APA

Liu, Z., Yang, Z., Wu, J., Zhang, W., Sun, Y., Zhang, C., Bai, G., Yang, L., Fan, H., Chen, Y., Zhang, L., Jiang, B., Liu, X., Ma, X., Tang, W., Liu, C., Qu, Y., Yan, L., Zhao, D., …, & Zhang, Z. (2025). A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell, 188(11), 3081-3096.e19. https://doi.org/10.1016/j.cell.2025.03.018

Vancouver

Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang C, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188(11):3081-3096.e19. doi:10.1016/j.cell.2025.03.018

BibTeX
@article{Liu2025,
  author = {Liu, Zedao and Yang, Zhenlin and Wu, Junqi and Zhang, Wenjie and Sun, Yuxuan and Zhang, Chao and Bai, Guangyu and Yang, Li and Fan, Hongtao and Chen, Yawen and Zhang, Lei and Jiang, Benyuan and Liu, Xiaoyan and Ma, Xiaoshi and Tang, Wei and Liu, Chang and Qu, Yang and Yan, Lixu and Zhao, Deping and Wu, Yilong and He, Shun and Xu, Long and Peng, Lishan and Chen, Xiaowei and Zhou, Bolun and Zhao, Liang and Zhao, Zhangyi and Tan, Fengwei and Zhang, Wanting and Yi, Dingcheng and Li, Xiangjie and Gao, Qianqian and Zhang, Guangjian and Wang, Yongjie and Yang, Minglei and Fu, Honghao and Guo, Yongjun and Hu, Xueda and Cai, Qingyuan and Qi, Lu and Bo, Yufei and Peng, Hui and Tian, Zhigang and She, Yunlang and Zou, Chang and Zhu, Linnan and Cheng, Sijin and Zhang, Yi and Zhong, Wenzhao and Chen, Chang and Gao, Shugeng and Zhang, Zemin},
  title = {A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer},
  journal = {Cell},
  year = {2025},
  volume = {188},
  number = {11},
  pages = {3081--3096.e19},
  doi = {10.1016/j.cell.2025.03.018}
}
Kostenlos starten →